The Selective Vasopressin Receptor Agonist Selepressin for Septic Shock скачать в хорошем качестве

The Selective Vasopressin Receptor Agonist Selepressin for Septic Shock

In a 2019 randomized trial, selepressin—a selective vasopressin V1a receptor agonist hypothesized to mitigate sepsis-induced vasodilatation, vascular leakage, and tissue edema because of its absence of V1b- or V2-mediated effects—did not improve vasopressor- and ventilator-free days at 30 days among patients with septic shock. Pierre-François Laterre, MD, of St. Luc University Hospital, Université Catholique de Louvain in Brussels, Belgium, presents findings from the SEPSIS-ACT trial at the European Society of Intensive Care Medicine (ESICM) 32nd Annual Congress, LIVES 2019, on October 2 in Berlin. Click https://ja.ma/2MRZiEO for full trial details. Video used with permission.